CME Opportunities

CME Opportunities

View More Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

All Oncology News

OncLive News Network®

Insights MedNews Week OncChats OncLive News Network®OncLive TV Peer Exchange Podcasts Rapid Readouts

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Giants of Cancer Care

Scientific Interchanges

State of the Science Summit / IPC

Giants of Cancer Care CME/CE Scientific Interchanges State of the Science Summit / IPC Webinars

Partners Publications

Consensus Viewpoints

Interactive Tools

Consensus Viewpoints OncLive App Interactive Tools Sponsored

Biomarker Consortium Subscribe

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2025 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

OncLive SOSS

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Next-Generation Agents for ALK-Positive NSCLC

EP. 1: The Evolution of ALK/ROS1-Targeted Therapy in NSCLC

April 27th 2017

EP. 2: Patterns of Progression on Crizotinib for ALK+ NSCLC

April 27th 2017

EP. 3: FDA Approval of Brigatinib for ALK+ NSCLC

April 27th 2017

EP. 4: ALTA II Trial of Brigatinib in ALK-Rearranged NSCLC

April 27th 2017

EP. 5: Repeat Mutation Testing at ALK-Rearranged NSCLC Progression

April 27th 2017

EP. 6: Treatment of Relapsed/Refractory ALK+ NSCLC

April 27th 2017

EP. 7: Upfront Use of Second-Line Agents in ALK+ NSCLC

April 27th 2017

EP. 8: Sequencing Therapies in ALK+ NSCLC

April 27th 2017

EP. 9: Treatment of ALK-Driven Refractory NSCLC

April 27th 2017

EP. 10: Next Generation ALK Inhibitors for NSCLC

April 27th 2017

<
1
2
>

x